Skip to search formSkip to main contentSkip to account menu

PSI 7977

Known as: 7977, PSI, PSI-7977, PSI7977 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

sofosbuvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The Discovery of Sofosbuvir: A Liver-Targeted Nucleotide Prodrug for the Treatment and Cure of HCV
Over the last 15 years, an increase in knowledge of the structure, function, life cycle, and pathogenesis of hepatitis C virus… 
2012
2012
1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?
Review
2012
Review
2012
1131 ACTIVE INJECTION DRUG USER'S CAN BE SUCCESSFULLY TREATED FOR HCV AND SIGNIFICANTLY REDUCE ILLICIT DRUG USE POST TREATMENT: REAL LIFE COHORT OF 152 PATIENTS
2012
2012
New agents for hepatitis C and the challenges in treating co‐infected patients
More recently, the improved understanding of the hepatitis C viral life cycle has led to the identification of numerous potential… 
2012
2012
Mono (PSI-7977), or combination treatment of DAA for use in the treatment of HCV
2012
2012
1 2 3 4 5 6 Genotype and Subtype Profiling of PSI-7977 as a 7 Nucleotide Inhibitor of Hepatitis C Virus 8 9 Running title : PSI-7977 as a Nucleotide Inhibitor of HCV 10 11
2011
2011
Chronic hepatitis C: treatments of the future.
Review
2010
Review
2010
FDA Pipeline Preview, September/October 2010 (Luveniq, Motavizumab, Ceftaroline fosamil, Dabigatran etexilate, Lorcaserin, Oxymorphone, Ipilimumab, Cladribine tablets, Iluvien, Vandetanib, ARC-4558…
Recent FDA action (through, August/September 2010) related to Luveniq, Motavizumab, Ceftaroline fosamil, Dabigatran etexilate… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)